Bio-Rad Laboratories Statistics
Total Valuation
BIO has a market cap or net worth of $8.02 billion. The enterprise value is $8.00 billion.
Important Dates
The next confirmed earnings date is Thursday, February 12, 2026, after market close.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO has 26.97 million shares outstanding. The number of shares has decreased by -3.14% in one year.
| Current Share Class | 21.91M |
| Shares Outstanding | 26.97M |
| Shares Change (YoY) | -3.14% |
| Shares Change (QoQ) | -1.12% |
| Owned by Insiders (%) | 6.49% |
| Owned by Institutions (%) | 74.92% |
| Float | 21.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 28.41 |
| PS Ratio | 3.20 |
| Forward PS | 3.02 |
| PB Ratio | 1.19 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | 23.82 |
| P/OCF Ratio | 16.32 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 19.16, with an EV/FCF ratio of 23.75.
| EV / Earnings | n/a |
| EV / Sales | 3.13 |
| EV / EBITDA | 19.16 |
| EV / EBIT | 31.31 |
| EV / FCF | 23.75 |
Financial Position
The company has a current ratio of 5.44, with a Debt / Equity ratio of 0.21.
| Current Ratio | 5.44 |
| Quick Ratio | 3.62 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 2.88 |
| Debt / FCF | 4.14 |
| Interest Coverage | 5.20 |
Financial Efficiency
Return on equity (ROE) is -9.50% and return on invested capital (ROIC) is 3.68%.
| Return on Equity (ROE) | -9.50% |
| Return on Assets (ROA) | 1.57% |
| Return on Invested Capital (ROIC) | 3.68% |
| Return on Capital Employed (ROCE) | 2.79% |
| Weighted Average Cost of Capital (WACC) | 9.56% |
| Revenue Per Employee | $332,143 |
| Profits Per Employee | -$87,779 |
| Employee Count | 7,700 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 1.54 |
Taxes
| Income Tax | -166.70M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.58% in the last 52 weeks. The beta is 1.18, so BIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -17.58% |
| 50-Day Moving Average | 310.94 |
| 200-Day Moving Average | 279.77 |
| Relative Strength Index (RSI) | 39.84 |
| Average Volume (20 Days) | 234,713 |
Short Selling Information
The latest short interest is 792,425, so 2.94% of the outstanding shares have been sold short.
| Short Interest | 792,425 |
| Short Previous Month | 898,989 |
| Short % of Shares Out | 2.94% |
| Short % of Float | 3.75% |
| Short Ratio (days to cover) | 4.10 |
Income Statement
In the last 12 months, BIO had revenue of $2.56 billion and -$675.90 million in losses. Loss per share was -$24.56.
| Revenue | 2.56B |
| Gross Profit | 1.34B |
| Operating Income | 255.50M |
| Pretax Income | -842.60M |
| Net Income | -675.90M |
| EBITDA | 417.60M |
| EBIT | 255.50M |
| Loss Per Share | -$24.56 |
Full Income StatementBalance Sheet
The company has $1.42 billion in cash and $1.40 billion in debt, with a net cash position of $23.30 million or $0.86 per share.
| Cash & Cash Equivalents | 1.42B |
| Total Debt | 1.40B |
| Net Cash | 23.30M |
| Net Cash Per Share | $0.86 |
| Equity (Book Value) | 6.74B |
| Book Value Per Share | 249.75 |
| Working Capital | 2.32B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $491.50 million and capital expenditures -$154.70 million, giving a free cash flow of $336.80 million.
| Operating Cash Flow | 491.50M |
| Capital Expenditures | -154.70M |
| Free Cash Flow | 336.80M |
| FCF Per Share | $12.49 |
Full Cash Flow StatementMargins
Gross margin is 52.36%, with operating and profit margins of 9.99% and -26.43%.
| Gross Margin | 52.36% |
| Operating Margin | 9.99% |
| Pretax Margin | -32.95% |
| Profit Margin | -26.43% |
| EBITDA Margin | 16.33% |
| EBIT Margin | 9.99% |
| FCF Margin | 13.17% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.14% |
| Shareholder Yield | 3.14% |
| Earnings Yield | -8.42% |
| FCF Yield | 4.20% |
Analyst Forecast
The average price target for BIO is $358.50, which is 20.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $358.50 |
| Price Target Difference | 20.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 1.55% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO has an Altman Z-Score of 3.34 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.34 |
| Piotroski F-Score | 4 |
